Tumor necrosis factora, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2

AIDS Research and Human Retroviruses

Volumn 18, Issue 7, 2002, Pages 491-499

  Fortis, Claudio ^a   Murone, Michelangelo ^a   Lazzarin, Adriano ^a   Poli, Guido ^a   Soldini, Laura ^a   Ghezzi, Silvia ^a   Colombo, Stefania ^a   Tambussi, Giuseppe ^a   Vicenzi, Elisa ^a   Gianotti, Nicola ^a   Nozza, Silvia ^a   Veglia, Fabrizio ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ISI FOUNDATION   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TOXICITY; BLOOD; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036013770     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202317406637     Document Type: Article

References (40)

1. Interleukin-2: Inception, impact, and implications
2. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
3. Use of interleukin-2 in patients with acquired immunodeficiency syndrome
4. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection
5. Prolonged administration of low dose interleukin-2 in human immunodeficiency-virus associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
6. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
7. Controlled trial of interleukin-2 infusion in patients infected with the human immunodeficiency virus
8. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
9. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV subjects
10. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens
11. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
12. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
13. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
14. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with 250/μL CD4 T cells and undetectable virus load
15. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
16. 3
17. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
18. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
19. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy
20. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment
21. Efficacy of low-dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected persons with detectable virus load: A controlled study of 3 IL-2 regimens with antiviral drug therapy
22. Serum level of cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-α increase during interleukin-2 therapy
23. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
24. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy
25. Tumor necrosis factor-alpha functions in an autocrine manner in the induction of HIV expression
26. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driver in an autocrine/paracrine manner by endogenous cytokines
27. Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV
28. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection
29. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation
30. Induction of HIV-1 replication in latently infected CD4 T cells using a combination of cytokines
31. Cytokines and chemokines in HIV infection
32. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
33. In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor
34. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation markers changes
35. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance function without toxicity
36. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immuno-deficiency virus infection
37. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients
38. Toxic effects of interleukin-2-activated lymphocytes on vascular endothelial cells
39. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma